Trial record 13 of 200 for:    endometriosis

Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women

This study has been completed.
Sponsor:
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
NCT00110487
First received: May 9, 2005
Last updated: December 7, 2007
Last verified: December 2007
  Purpose

The purpose of this investigational study is to determine if a study medication is safe and effective in reducing the symptoms associated with endometriosis; if the study medication reduces the need for pain medication for endometriosis symptoms; and if the study medication improves a participant's ability to carry out daily activities. Qualified participants will receive no cost treatment, which may include study-related examinations, diagnostic procedures including a Pap smear, laboratory testing, and a mammogram (aged 40-45). Qualified participants will also receive study medication at no cost. As a participant, the study volunteer may also experience the satisfaction of knowing she is helping the advancement of women’s health care.


Condition Intervention Phase
Endometriosis
Drug: ERB-041
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study of the Effect of ERB-041 in the Reduction of Symptoms Associated With Endometriosis in Reproductive-Age Women

Resource links provided by NLM:


Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • To assess the effects and to compare the safety profile of an investigational
  • medication on the relief of endometriosis-related symptoms.

Secondary Outcome Measures:
  • Clinical and subject assessment of symptoms related to endometriosis and the
  • use of analgesia to relieve symptoms.

Estimated Enrollment: 200
Study Start Date: January 2005
Study Completion Date: December 2006
  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: Surgical diagnosis of endometriosis within 5 years not pregnant and not lactating willing to use non-hormonal contraception, history of regular menstrual cycles. Exclusion Criteria: Hysterectomy, surgical treatment for endometriosis within 3 months certain medications for the treatment of endometriosis previous history of a malignancy abnormalities on physical or gyn exams and abnormal lab tests 

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00110487

  Show 46 Study Locations
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00110487     History of Changes
Other Study ID Numbers: 3142A2-200
Study First Received: May 9, 2005
Last Updated: December 7, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
Endometriosis

Additional relevant MeSH terms:
Endometriosis
Genital Diseases, Female

ClinicalTrials.gov processed this record on September 18, 2014